Essex Bio-Technology (HKG:1061) said the anti-VEGF ophthalmic injection bio-pharmaceutical product, HLX04-O, co-developed by two of its subsidiaries and Shanghai Henlius Biotech (HKG:2696), saw the last visit of the last patient (LPLV) for its phase 3 clinical study.

The study is a randomized, double-blinded, active-controlled, and global study conducted in patients with exudative age-related macular degeneration or wet-AMD, a Monday Hong Kong bourse filing said.

The drug is a new ophthalmic preparation product and is planned to be used for the treatment of wet-AMD in China.